Sunday 18 October 2026 Export VJET’s income statement to Excel — free account

Flyte Aviation, Inc.

Flyte Aviation, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $819,000.00, up 95.0% from fiscal 2024. In the quarter to June 2026, revenue grew 380.7%, EPS grew 87.3%, free cash flow fell 26.7% and total debt rose 160.0%, each against the same quarter a year earlier. Operating cash flow growth for five consecutive years.

0.84 0.14 −14.29%

Follow VJET

Alert me

Market cap: $2.1M
P/E: 0.0×
Fwd P/E: −0.9×
Dividend yield: —
F-score: 3/9
Altman Z: −30.65
Beneish M: −4.90
Dividend safety: n/a

Overview Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 81.57%

Capital & Financial Ratios $m

Market Cap 2.06

Revenue 1.92

Net Income (13.19)

Free Cash Flow (9.37)

Net Debt 1.45

Current Ratio 0.19

Debt/Equity 0.19

P/E ratio 0.00

Fwd P/E (0.89)

P/S ratio 1.21

P/B ratio 0.14

Past 5Y EPS Growth —

This Y EPS Growth 93.15%

Next Y EPS Growth 29.21%

Next Y revenue growth 1,149.08%

Next 5Y EPS Growth 70.90%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.05%

10-year low 10-year high

P/B against its own 10 years 0.05%

10-year low 10-year high

EV/Sales against its own 10 years 0.05%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	4	3	0	2
Receivables	0	0	0	0
Inventory	0	0	0	0
Other	—	—	—	—
	4	3	0	3

	2023	2024	2025	Q'26
Payables	0	0	1	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	2	2	4	13

Compound Annual Growth %

	10y	5y	3y
Sales	—	25.89%	288.20%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(20.65%)	(10.44%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	1	—	—	—
’25	0	0	0	0	1
’24	0	0	0	0	0
’23	0	0	0	0	0
’22	0	0	—	0	0
’21	0	0	0	0	0
’20	1	1	0	(2)	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(3)	—	—	—
’25	(2)	(2)	(2)	(2)	(8)
’24	(2)	(2)	(3)	(3)	(9)
’23	(12)	(5)	(2)	(2)	(21)
’22	(9)	(6)	(5)	(3)	(23)
’21	(8)	(7)	(7)	(6)	(28)
’20	(7)	(6)	(6)	(9)	(28)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(3)	—	—	—
’25	(2)	(2)	(2)	(2)	(8)
’24	(2)	(2)	(3)	(3)	(9)
’23	(12)	(5)	(2)	(2)	(21)
’22	(9)	(6)	(5)	(3)	(23)
’21	(8)	(6)	(7)	(6)	(27)
’20	(7)	(6)	(6)	(9)	(28)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.39)	(0.92)	—	—	—
’25	(6.84)	(7.22)	(1.70)	(2.88)	(15.90)
’24	(68.44)	(105.89)	(38.21)	115.66	(127.00)
’23	(4.63k)	(55.13)	(53.23)	2.30k	(2.47k)
’22	(2.57k)	(2.47k)	(828.90)	980.34	(4.94k)
’21	(23.57k)	(12.17k)	(6.37k)	(11.69k)	(47.15k)
’20	(133.08k)	(102.19k)	(30.89k)	(34.32k)	(201.71k)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	16,981,250.00	1,662,500.00	403,750.00	140,600.00	3,857.00	646.00	58.90	14.90	Analyst estimates 2026–2028 Powerpack
	High	—	—	52,250,000.00	24,201,250.00	6,388,750.00	932,900.00	160,550.00	13,775.00	1,596.00	157.70
People
People	Employees	—	75	118	79	85	58	14	14	22	17
	Revenue/emp, $m	0.00	0.08	0.05	0.09	0.00	0.00	0.00	0.03	0.02	0.05
Income, $m
Income, $m	Revenue	6	6	6	7	0	0	0	0	0	1
	Gross margin, %	47.49	29.05	32.78	(22.93)	(738.61)	(6,990.91)	(1,050.00)	93.21	90.00	92.31
	EBT	(4)	(18)	(31)	(57)	(35)	(27)	(27)	(71)	(14)	(20)
	EBT margin, %	(70.30)	(302.62)	(492.60)	(790.97)	(13,634.36)	(123,895.45)	(191,871.43)	(15,966.52)	(3,214.76)	(2,381.56)
	Net income	(4)	(18)	(31)	(57)	(36)	(25)	(27)	(71)	(17)	(18)
	Depreciation	0	0	1	2	2	2	0	2	2	2
Per share, $
Per share, $	Revenue	11.77	0.78	0.68	71,990.00	1,295.00	44.00	2.59	15.29	2.44	0.76
	Earnings	(8.28)	(2.35)	(3.34)	(1,028,992.00)	(201,711.00)	(47,148.29)	(4,940.32)	(2,469.58)	(127.00)	(15.90)
	Cash flow	(3.72)	(0.73)	(2.01)	(331,730.00)	(141,520.00)	(55,250.00)	(4,179.26)	(713.46)	(53.96)	(7.68)
	Capex	0.00	(0.07)	(0.06)	(2,680.00)	(335.00)	658.00	3.89	(2.63)	(0.39)	(0.02)
	Free cash flow	(3.72)	(0.80)	(2.07)	(334,410.00)	(141,855.00)	(54,592.00)	(4,175.37)	(716.09)	(54.35)	(7.69)
	Book value	(0.75)	(1.01)	7.23	331,500.00	105,735.00	27,346.00	1,714.81	733.32	68.43	6.15
	Shares, m	1	8	9	0	0	0	0	0	0	1
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.00	0.00	27,852,635.05	37.28	545.06	4,510.43	3,407.40	49.69	34.97	24.15
	P/B	0.00	0.00	2,612,606.81	8.10	6.68	7.59	6.99	1.04	1.25	2.97
	EV/Sales	0.00	0.00	27,852,624.91	33.11	459.88	3,953.96	2,678.56	42.43	32.48	28.12
	EV/FCF	(31,363,839.83)	(31,363,839.83)	(9,129,066.21)	(7.13)	(4.20)	(3.33)	(2.26)	(0.91)	(1.46)	(2.77)
Cash, $m
Cash, $m	Operating cash flow	(2)	(6)	(19)	(33)	(28)	(28)	(23)	(21)	(9)	(8)
	Capex	0	(1)	(1)	0	0	0	0	0	0	0
	Free cash flow	(2)	(6)	(19)	(33)	(28)	(27)	(23)	(21)	(9)	(8)
Balance, $m
Balance, $m	Working capital	3	7	63	29	20	12	9	2	1	(4)
	Total debt	0	0	1	1	2	2	—	—	2	3
	Net debt	(4)	(8)	(63)	(30)	(22)	(13)	(16)	(4)	(1)	3
	Shareholders’ equity	0	(8)	67	33	21	14	9	21	12	7
Returns, %
Returns, %	ROA	(49.11)	(207.64)	(72.29)	(96.44)	(93.00)	(92.03)	(141.84)	(300.06)	(74.53)	(78.77)
	ROIC	0.00	0.00	(601.08)	(1,152.39)	0.00	(3,003.49)	0.00	(276.97)	(67.28)	(137.06)
	ROE	105.12	444.40	(104.36)	(114.08)	(132.77)	(144.00)	(234.29)	(468.74)	(132.33)	(186.69)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ADGM Adagio Medical Holdings, Inc.	$2.8M	— (loss-making)	—	−33.50% (below 0%: shrinking)	n/m	−12.86% (below 0%: shrinking)	0.00%	0.00%	Compare
NXL Nexalin Technology, Inc.	$2.6M	— (loss-making)	— (loss-making)	−82.72% (below 0%: shrinking)	n/m	−97.23% (below 0%: shrinking)	72.95%	(18,420.49%)	Compare
BIOLQ Biolase, Inc.	$2.3M	— (loss-making)	— (loss-making)	−0.65% (below 0%: shrinking)	n/m	−60.22% (below 0%: shrinking)	40.39%	(6.41%)	Compare
XAIR Beyond Air, Inc.	$2.2M	— (loss-making)	— (loss-making)	+0.45% (above 0%: growing)	n/m	−9.10% (below 0%: shrinking)	12.73%	(373.98%)	Compare
NUVOQ Holdco Nuvo Group D.G Ltd.	$2.1M	— (loss-making)	—	—	n/m	−1.05% (below 0%: shrinking)	0.00%	0.00%	Compare
VJET Flyte Aviation, Inc.	$2.1M	— (loss-making)	— (loss-making)	+380.66% (above 0%: growing)	n/m	−26.70% (below 0%: shrinking)	9.62%	(388.13%)
NUWE Nuwellis, Inc.	$2.0M	— (loss-making)	— (loss-making)	+14.14% (above 0%: growing)	n/m	−51.55% (below 0%: shrinking)	76.08%	(160.94%)	Compare
AFIB Acutus Medical, Inc.	$1.7M	— (loss-making)	— (loss-making)	+204.18% (above 0%: growing)	n/m	+76.40% (above 0%: growing)	14.20%	(3.81%)	Compare
DHAI DIH Holding US, Inc.	$1.6M	— (loss-making)	—	−30.67% (below 0%: shrinking)	n/m	−167.90% (below 0%: shrinking)	50.33%	(33.62%)	Compare
Median of peers	$2.2M	—	—	−0.65%	—	−32.20%	27.29%	(20.01%)

All 149 Medical Devices stocks →

Flyte Aviation, Inc. (VJET) key facts

Strength: Flyte Aviation, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $819,000.00, up 95.0% from fiscal 2024.
Flyte Aviation, Inc. (VJET) is a Medical Devices company in the Healthcare sector, listed on NYSE American.
As of October 16, 2026, VJET traded at $0.84, a market capitalization of $2.1 million.
Return on equity was −186.7% and debt-to-equity 0.19.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −30.65 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.